The biomedical model of mental disorder: A critical analysis of its validity, utility, and effects on psychotherapy research

Clinical Psychology Review

Volumn 33, Issue 7, 2013, Pages 846-861

  Deacon, Brett J ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

Biomedical model; Biopsychosocial model; Chemical imbalance; Disease; Psychotherapy; Treatment

Indexed keywords

OLANZAPINE; PERPHENAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ATTENTION DEFICIT DISORDER; BIOMEDICAL MODEL; BRAIN DISEASE; CHRONICITY; CLINICAL PSYCHOLOGY; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; HEALTH CARE POLICY; HUMAN; MAJOR DEPRESSION; MEDICAL RESEARCH; MENTAL DISEASE; MOLECULAR BIOLOGY; NATIONAL HEALTH ORGANIZATION; NEW ZEALAND; PATIENT ADVOCACY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SOCIAL STIGMA; SUBSTANCE ABUSE; UNITED STATES;

BIOMEDICAL MODEL; BIOPSYCHOSOCIAL MODEL; CHEMICAL IMBALANCE; DISEASE; PSYCHOTHERAPY; TREATMENT;

BIOLOGICAL PSYCHIATRY; EVIDENCE-BASED PRACTICE; HUMANS; MENTAL DISORDERS; PSYCHOLOGICAL THEORY; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84883197540     PISSN: 02727358     EISSN: 18737811     Source Type: Journal    
DOI: 10.1016/j.cpr.2012.09.007     Document Type: Review

References (191)

1. Abramowitz J.S. Toward a functional analytic approach to psychologically complex patients: A comment on Ruscio and Holohan. Clinical Psychology: Science and Practice 2006, 13:163-166.
2. Addis M.E., Wade W.A., Hatgis C. Barriers to dissemination of evidence-based practices: Addressing practitioners concerns about manual-based psychotherapies. Clinical Psychology: Science and Practice 1999, 6:430-441.
3. Albee G.W., Joffe J.M. Mental illness is NOT an "illness like any other". The Journal of Primary Prevention 2004, 24:419-436.
4. American College of Neuropsychopharmacology Public education committee's comment on commentary by John Krystal titled Marcia Angell and the illusions of anti-psychiatry 2012, July 31, (Retrieved August 6, 2012, fromhttp://www.acnp.org/comments.aspx?tid=184de4aa-7783-4cbd-8e37-eb5e4a01f70a&ttitle=Dr. Marcia Angell and the Illusions of Anti-Psychiatry&returnUrl=http%3a%2f%2fwww.acnp.org%2fresources%2farticlediscussionDetail.aspx%3fcid%3d66d1c1bf-7c40-4af9-b4f5-a3856fe1b5ba).
5. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1980, Author, Washington, DC. 3th ed.
6. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, Author, Washington, DC, (text revision). 4th ed.
7. American Psychiatric Association Practice guideline for the treatment of patients with bipolar disorder 2002, Author, Arlington, VA. 2nd ed.
8. American Psychiatric Association Letter from American Psychiatric Association to Fast for Freedom in Mental Health Retrieved June 25, 2012, from. http://www.mindfreedom.org/kb/act/2003/mf-hunger-strike/hunger-strike-debate/apa-1st-reply-to-mfi.
9. American Psychiatric Association Statement on diagnosis and treatment of mental disorders (Release no. 03-39) Retrieved June 12, 2012, from. http://www.critpsynet.freeuk.com/APA.htm.
10. American Psychiatric Association APA responds to Tom Cruise's anti-psychiatry remarks Retrieved June 25, 2012, from. http://www.nami.org/Template.cfm?Section=June4&Template=/ContentManagement/ContentDisplay.cfm&ContentID=24249.
11. American Psychiatric Association "60 Minutes" segment on antidepressants "irresponsible and dangerous" Retrieved March 6, 2012, from. http://www.psychiatry.org/advocacy--newsroom/news-releases/news-releases.
12. American Psychiatric Association. (n.d.). DSM-5: The future of psychiatric diagnosis. Retrieved February 18, 2012, from http://www.dsm5.org/Pages/Default.aspx.
13. Andreasen N.C. The broken brain: The biological revolution in psychiatry 1985, Harper & Row, New York.
14. Angell M. The epidemic of mental illness: Why? The New York Times Review of Books Retrieved February 18, 2012, from. http://www.nybooks.com/articles/archives/2011/jun/23/epidemic-mental-illness-why/.
15. Angell M. The illusions of psychiatry. The New York Times Review of Books Retrieved February 18, 2012, from. http://www.nybooks.com/articles/archives/2011/jul/14/illusions-of-psychiatry/.
16. Angermeyer M.C., Matschinger H. Labeling-stereotype-discrimination: An investigation of the stigma process. Social Psychiatry and Psychiatric Epidemiology 2005, 40:391-395.
17. Antonuccio D.O., Burns D.M., Danton W.G. Antidepressants: A triumph of marketing over science?. Prevention and Treatment 2002, 5. (no. 25. Retrieved February 18, 2012, fromhttp://web.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=89589bd0-1a0a-40f5-a899-d809b70cefbf%40sessionmgr10&vid=4&hid=113).
18. Antonuccio D.O., Danton W.G., McClanahan T.M. Psychology in the prescription era: Building a firewall between marketing and science. American Psychologist 2003, 58:1028-1043.
19. Bach P., Hayes S.C. The use of acceptance and commitment therapy to prevent the rehospitalization of psychotic patients: A randomized controlled trial. Journal of Consulting and Clinical Psychology 2002, 70:1129-1139.
20. Baker T.B., McFall R.M., Shoham V. Current status and future prospects of clinical psychology. Psychological Science in the Public Interest 2009, 9:67-103.
21. Barlow D.H. Psychological treatments. American Psychologist 2004, 59:869-878.
22. Barlow D.H., Allen L.B., Choate M.L. Toward a unified treatment for emotional disorders. Behavior Therapy 2004, 35:205-230.
23. Barlow D.H., Farchione T.J., Fairholme C.P., Ellard K.K., Boiseau C.L., Allen L.B., et al. Unified protocol for transdiagnostic treatment of emotional disorders: Therapist guide 2011, Oxford University Press, New York.
24. Barlow D.H., Gorman J.M., Shear M.K., Woods S.W. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Journal of the American Medical Association 2000, 283:2529-2536.
25. Begley S. The depressing news about antidepressants [Electronic version] 2010, January 28, Newsweek, (Retrieved February 18, 2012, fromhttp://www.thedailybeast.com/newsweek/2010/01/28/the-depressing-news-about-antidepressants.html).
26. Beitman B.D. Psychotherapy research: "Horse race" versus process. Journal of Psychiatric Practice 2004, 10:386-388.
27. Bell J. The Today Show [Television broadcast] 2005, June 27, National Broadcasting Company, New York, (Executive Producer).
28. Bell J. The Today Show [Television broadcast] 2005, June 24, National Broadcasting Company, New York, (Executive Producer).
29. Bola J.R., Mosher L.R. Treatment of acute psychosis without neuroleptics: Two-year outcomes from the Soteria Project. The Journal of Nervous and Mental Disease 2003, 191:219-229.
30. 1 Boring Old Man Not a toy. . Retrieved June 27, 2012, from. http://1boringoldman.com/index.php/2012/06/09/not-a-toy/.
31. Cahn C.H., Lehmann H.E. Perphenazine: Observations on the clinical effects of a new tranquillizing agent in psychotic conditions. Canadian Psychiatric Association Journal 1957, 2:104-112.
32. Carlat D. Unhinged: The trouble with psychiatry - A doctor's revelations about a profession in crisis 2010, Free Press, New York.
33. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
34. Principles of therapeutic change that work 2006, Oxford University Press, New York. L.G. Castonguay, L.E. Beutler (Eds.).
35. Chambless D.L., Hollon S.D. Defining empirically supported therapies. Journal of Consulting and Clinical Psychology 1998, 66:7-18.
36. Chambless D.L., Ollendick T.H. Empirically supported psychological interventions: Controversies and evidence. Annual Review of Psychology 2011, 52:685-716.
37. Children & Adults with Attention Deficit/Hyperactivity Disorder (n.d.). Understanding ADHD. Retrieved February 18, 2012, from http://www.chadd.org/AM/Template.cfm?Section=Understanding.
38. Clark D.M. Anxiety disorders: Why they persist and how to treat them. Behaviour Research and Therapy 1999, 37:S5-S27.
39. Cole J.O. Therapeutic efficacy of antidepressant drugs: A review. Journal of the American Medical Association 1964, 190:448-455.
40. Coryell W., Endicott J., Winokur G., Akisal H., Solomon D., Leon A., et al. Characteristics and significance of untreated major depressive disorder. The American Journal of Psychiatry 1995, 152:1124-1129.
41. Davis D. Losing the mind. Los Angeles Times Retrieved June 25, 2012, from. http://articles.latimes.com/2003/oct/26/magazine/tm-survivors43.
42. Deacon B.J., Baird G. The chemical imbalance explanation of depression: Reducing blame at what cost?. Journal of Clinical and Social Psychology 2009, 28:415-435.
43. Deacon B.J., Lickel J.J. On the brain disease model of mental disorders. The Behavior Therapist 2009, 32:113-118.
44. Depression and Bipolar Support Alliance Depression Retrieved February 18, 2012, from. http://www.dbsalliance.org/site/PageServer?pagename=about_depression_overview.
45. Devilly G.J. Eye movement desensitization and reprocessing: A chronology of its development and scientific standing. The Scientific Review of Mental Health Practice 2002, 1:113-138.
46. Douglas, M., & Zaentz, S. (Producers), & Forman, M. (1975). One flew over the cuckoo's nest [Motion picture]. United States: United Artists.
47. Eifert G.H. More theory-driven and less diagnosis-based behavior therapy. Journal of Behavior Therapy and Experimental Psychiatry 1996, 27:75-86.
48. Elkin I. The NIMH Treatment of Depression Collaborative Research Program: Where we began and where we are. Handbook of psychotherapy and behavior change 1994, Wiley, New York. A.E. Bergin, S.L. Garfield (Eds.).
49. El-Mallakh R.S., Gao Y., Roberts R.J. Tardive dysphoria: The role of long term antidepressant use in inducing chronic depression. Medical Hypotheses 2011, 76:769-773.
50. Engel G.L. The need for a new medical model: a challenge for biomedicine. Science 1977, 196:129-136.
51. Fairburn C.G., Cooper Z., Shafran R. Cognitive behaviour therapy for eating disorders: A "transdiagnostic" theory and treatment. Behaviour Research and Therapy 2003, 41:509-528.
52. Families Empowered and Supporting Treatment of Eating Disorders The role of environment Retrieved February 18, 2012, from. http://www.feast-ed.org/TheFacts/CausesofEatingDisorders/Theroleofenvironment.aspx.
53. Fava G.A. Can long-term treatment with antidepressant drugs worsen the course of depression?. The Journal of Clinical Psychiatry 2003, 64:123-133.
54. Fava G.A., Offidani E. The mechanisms of tolerance in antidepressant action. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 15:1593-1602.
55. Fibiger H.C. Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophrenia Bulletin 2012, 38:649-650.
56. First M.B. A research agenda for DSM-V: Summary of the white papers. Psychiatric Research Report 2002, 18:10-13.
57. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., et al. Randomized, placebo-controlled trial of exposure and ritual prevention, cmomipramine, and their combination in the treatment of obsessive-compulsive disorder. The American Journal of Psychiatry 2005, 162:151-161.
58. Foa E.B., Rothbaum B.O. Treating the trauma of rape: Cognitive-behavioral therapy for PTSD 1998, Guilford Press, New York.
59. France C.M., Lysaker P.H., Robinson R.P. The "chemical imbalance" explanation for depression: Origins, lay endorsement, and clinical implications. Professional Psychology: Research and Practice 2007, 38:411-420.
60. Frances A. A warning sign on the road to DSM-V: Beware of its unintended consequences [Electronic version]. Psychiatric News 2009, June 26, (Retrieved February 18, 2012, fromhttp://www.psychiatrictimes.com/dsm-5/content/article/10168/1425378).
61. Frances A. Public relations fictions trying to hide DSM-5 facts Retrieved June 29, 2012, from. http://www.psychologytoday.com/blog/dsm5-in-distress/201206/public-relations-fictions-trying-hide-dsm-5-facts.
62. Frances A., Widiger T. Psychiatric diagnosis: Lessons from the DSM-IV past and cautions for the future. Annual Review of Clinical Psychology 2012, 8:109-130.
63. Franklin J. The mind-fixers. Baltimore Evening Sun Retrieved June 27, 2012, from. http://www.baltimoresun.com/media/acrobat/2010-05/53724305.pdf.
64. Gold I. Reduction in psychiatry. Canadian Journal of Psychiatry 2009, 54:506-512.
65. Goldfried M.R., Wolfe B.E. Toward a more clinically valid approach to therapy research. Journal of Consulting and Clinical Psychology 1998, 66:143-150.
66. Gray M.J., Elhai J.D., Schmidt L.O. Trauma professionals' attitudes toward and utilization of evidence-based practices. Behavior Modification 2007, 31:732-748.
67. Harrow M., Jobe T.H. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A 15-year multifollow-up study. The Journal of Nervous and Mental Disease 2007, 195:406-414.
68. Harvey A., Watkins E., Mansell W., Shafran R. Cognitive behavioural processes across the psychological disorders: A transdiagnostic approach to research and treatment 2004, Oxford University Press, New York.
69. Haslam N. Genetic essentialism, neuroessentialism, and stigma: Commentary on Dar-Nimrod and Heine (2011). Psychological Bulletin 2011, 137:819-824.
70. Hayes A.M., Laurenceau J.-P., Cardaciotto L. Methods for capturing the process of change. Evidence-based outcome research: A practical guide to conducting randomized controlled trials for psychosocial interventions 2008, 335-358. Oxford University Press, New York. A.M. Nezu, C.M. Nezu (Eds.).
71. Hayes S.C., Strosahl K.D., Wilson K.G. Acceptance and commitment therapy: An experiential approach to behavior change 1999, Guilford Press, New York.
72. Healy D. The anti-depressant era 1997, Harvard University Press, Cambridge, MA.
73. Healy D. Pharmageddon 2012, University of California Press, Berkeley and Los Angeles, CA.
74. Heimberg R.G., Becker R.E. Cognitive-behavioral group therapy for social phobia: Basic mechanisms and clinical strategies 2002, Guilford Press, New York.
75. Hyman S.E. The diagnosis of mental disorders: The problem of reification. Annual Review of Clinical Psychology 2010, 6:155-179.
76. IMS Institute for Healthcare Informatics Top therapeutic classes by U.S. spending Retrieved February 18, 2012, from. http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011%20Top-line%20Market%20Data/Top_Therapy_Classes_by_Sales.pdf.
77. IMS Institute for Healthcare Informatics (n.d.). Total US promotional spend by type, 2010. Retrieved June 13, 2012, from http://www.imshealth.com/ims/Global/Content/Corporate/Press%20Room/Top-line%20Market%20Data/2010%20Top-line%20Market%20Data/2010_Promotional_Data.pdf.
78. Insel T.R. Testimony during the hearing, Mental Illness and brain disease: Dispelling myths and promoting recovery through awareness and treatment. Subcommittee on Health of the Committee on Energy and Commerce, United States House of Representatives Retrieved August 2, 2012, from. http://www.gpo.gov/fdsys/pkg/CHRG-109hhrg30414/html/CHRG-109hhrg30414.htm.
79. Insel T.R. Neuroscience: Shining light on depression. Science 2007, 317:757-758.
80. Insel T.R. Translating scientific opportunity into public health impact: A strategic plan for research on mental illness. Archives of General Psychiatry 2009, 66:128-133.
81. Insel T.R. Faulty circuits. Scientific American 2010, 302:44-51.
82. Insel T.R. Mental illness defined as disruption in neural circuits Retrieved February 18, 2012, from. http://www.nimh.nih.gov/about/director/2011/mental-illness-defined-as-disruption-in-neural-circuits.shtml.
83. Insel T.R. Experimental medicine Retrieved June 25, 2012, from. http://www.nimh.nih.gov/about/director/2012/experimental-medicine.shtml.
84. Insel T.R. The top ten research advances of 2012 Retrieved February 2, 2013, from. http://www.nimh.nih.gov/about/director/2012/the-top-ten-research-advances-of-2012.shtml.
85. Insel, T. R., & Quirion, R. (n.d.). Psychiatry as a clinical neuroscience discipline [Electronic version]. Retrieved February 18, 2012, from. http://www.nimh.nih.gov/about/director/publications/psychiatry-as-a-clinical-neuroscience-discipline.shtml.
86. Jensen P.S., Arnold L.E., Swanson J.M., Vitiello B., Abikoff H.B., Greenhill L.L., et al. 3-Year follow-up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46:989-1002.
87. Jorm A.F. National surveys of mental disorders: Are they researching scientific facts or constructing useful myths?. The Australian and New Zealand Journal of Psychiatry 2006, 40:830-834.
88. Kendler K.S. Toward a philosophical structure for psychiatry. The American Journal of Psychiatry 2005, 162:433-440.
89. Kendler K.S. Levels of explanation in psychiatric and substance use disorders: Implications for the development of an empirically based nosology. Molecular Psychiatry 2012, 17:11-21.
90. Kendler K.S., Schaffner K.F. The dopamine hypothesis of schizophrenia: An historical and philosophical analysis. Philosophy in Psychiatry and Psychology 2011, 18:41-63.
91. Kessler R.C., Chiu W.T., Demler O., Walters E.E. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the national comorbidity survey replication (NCS-R). Archives of General Psychiatry 2005, 62:617-627.
92. Kessler R.C., Demler O., Frank R.G., Olfson M., Pincus H.A., Walters E.E., et al. Prevalence and treatment of mental disorders, 1990 to 2003. The New England Journal of Medicine 2005, 352:2515-2523.
93. Kiesler D.J. Beyond the disease model of mental disorders 2000, Praeger, Westport, CT.
94. Kirsch I. The emperor's new drugs: Exploding the antidepressant myth 2010, Basic Books, New York.
95. Klerman G., Vaillant G., Spitzer R., Michels R. A debate on DSM-III: The advantages of DSM-III. The American Journal of Psychiatry 1984, 141:539-553.
96. Kozak M.J., Foa E.B. Mastery of obsessive-compulsive disorder: A cognitive-behavioral approach 1997, Graywind Publications, San Antonio, TX.
97. Kraemer H.C., Wilson G.T., Fairburn C.G., Agras W.S. Mediators and moderators of treatment effects in randomized clinical trials. Archives of General Psychiatry 2002, 59:877-883.
98. Kramer P.D. In defense of antidepressants. The New York Times Retrieved June 25, 2012, from. http://www.nytimes.com/2011/07/10/opinion/sunday/10antidepressants.html.
99. Kravitz R.L., Epstein R.M., Feldman M.D., Franz C.E., Azari R., Wilkes M.S., et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. Journal of the American Medical Association 2005, 293:1995-2002.
100. Lacasse J., Leo J. Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Medicine 2005, 2:1211-1216.
101. Laing R.D. The divided self: An existential study in sanity and madness 1960, Penguin Books, New York.
102. Lam D.C.K., Salkovskis P.M. An experimental investigation of the impact of biological and psychological causal explanations on anxious and depressed patients' perception of a person with panic disorder. Behaviour Research and Therapy 2006, 45:405-411.
103. Lasalle J.M., Yasui D.H. Evolving role of MeCP2 in Rett syndrome and autism. Epigenomics 2009, 1:119-130.
104. Leffingwell T.R., Claborn K. Biological bias in National Institute of Mental Health consumer brochures for psychological disorders. Clinical Psychologist 2010, 63:5-9.
105. Leo J., Lacasse J.R. The media and the chemical imbalance theory of depression. Society 2008, 45:35-45.
106. Lepine J.P., Briley M. The increasing burden of depression. Neuropsychiatric Disease and Treatment 2011, 7:3-7.
107. Levant R.F. The empirically validated treatments movement: A practitioner/educator perspective. Clinical Psychology: Science and Practice 2004, 11:219-224.
108. Lieberman J.A., Stroup T.S., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005, 353:1209-1223.
109. Lilienfeld S.O. Cognitive neuroscience and depression: Legitimate versus illegitimate reductionism and five challenges. Cognitive Therapy and Research 2007, 31:263-272.
110. Mayo Clinic Depression (major depression Retrieved February 18, 2012, from. http://www.mayoclinic.com/health/antidepressants/MM00660.
111. McHugh R.K., Barlow D.H. The dissemination and implementation of evidence-based psychological treatments. American Psychologist 2010, 65:73-84.
112. Medco Health Solutions America's state of mind Retrieved June 13, 2012, from. http://apps.who.int/medicinedocs/en/m/abstract/Js19032en/.
113. Merikangas K.R., Jin R., He J.-P., Kessler R.C., Lee S., Sampson N.A., et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Archives of General Psychiatry 2011, 68:241-251.
114. Miller G.A. Mistreating psychology in the decade of the brain. Perspectives on Psychological Science 2010, 5:716-743.
115. MindFreedom Original statement by the Fast for Freedom in Mental Health Retrieved June 29, 2012, from. http://www.mindfreedom.org/kb/act/2003/mf-hunger-strike/hunger-strike-debate/fast-for-freedom-statement.
116. MindFreedom Reply by scientific panel of the Fast for Freedom in Mental Health to the 26 September statement by American Psychiatric Association Retrieved June 29, 2012, from. http://www.mindfreedom.org/kb/act/2003/mf-hunger-strike/hunger-strike-debate/mfi-2nd-reply-to-apa.
117. Mojtabai R., Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry 2010, 67:26-36.
118. Molina B.S., Hinshaw S.P., Swanson J.M., Arnold L.E., Jensen P.S., Epstein J.N., et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48:484-500.
119. Moncrieff J. The myth of the chemical cure: A critique of psychiatric drug treatment 2008, Palgrave Macmillan, Basingstoke, Hampshire.
120. Moncrieff J., Cohen D. Do antidepressants create or cure abnormal brain states?. PLoS Medicine 2006, 3:961-965.
121. Moreno C., Laje G., Blanco C., Jiang H., Schmidt A.B., Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry 2007, 64:1032-1039.
122. Murphy R., Cooper Z., Hollon S.D., Fairburn C.G. How do psychological treatments work? Investigating mediators of change. Behaviour Research and Therapy 2009, 47:1-5.
123. Nathan P.E., Gorman J.M. A guide to treatments that work 2007, Oxford University Press, New York. 3rd ed.
124. National Alliance on Mental Illness (n.d., a). Transforming mental health care in America. Retrieved February 18, 2012, from. http://www.nami.org/Template.cfm?section=Mind_of_America_Foundation.
125. National Alliance on Mental Illness (n.d., b). What is mental illness: Mental illness facts. Retrieved February 18, 2012, from. http://www.nami.org/Content/NavigationMenu/Inform_Yourself/About_Mental_Illness/About_Mental_Illness.htm.
126. National Alliance on Mental Illness (n.d., c). Obsessive-compulsive disorder. Retrieved February 18, 2012, from. http://www.nami.org/Template.cfm?Section=By_Illness&Template=/TaggedPage/TaggedPageDisplay.cfm&TPLID=54&ContentID=23035.
127. National Institute of Mental Health When unwanted thoughts take over: Obsessive-compulsive disorder 2009, [Brochure], Author, Washington, DC, (Retrieved December 9, 2009, fromhttp://www.nimh.gov/health/publications/when-unwanted-thoughts-take-over-obsessive-com;pulsive-disorder/complete.pdf).
128. National Institute of Mental Health When unwanted thoughts take over: Obsessive-compulsive disorder 2010, [Brochure], Author, Washington, DC, (Retrieved February 18, 2012, from
129. National Institute of Mental Health Mental health medications (NIH Pub No. 12-3929) 2012, Author, Washington, DC, (Retrieved July 31, 2012, fromhttp://www.nimh.nih.gov/health/publications/mental-health-medications/nimh-mental-health-medications.pdf).
130. National Institute on Alcohol Abuse and Alcoholism FAQs for the general public Retrieved February 18, 2012, from. http://www.niaaa.nih.gov/FAQs/General-English/Pages/default.aspx#disease.
131. National Institute on Drug Abuse Drugs, brains, and behavior: The science of addiction (NIH Pub No. 10-5605) 2010, Author, Washington, DC, (Retrieved February 18, 2012, fromhttps://www.drugabuse.gov/sites/default/files/sciofaddiction.pdf).
132. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008, 63:1118-1126.
133. O'Brien C. Drug firm to drop non-addiction claim. Irish Times 2003, October 5.
134. Olfson M., Blanco C., Liu L., Moreno C., Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 2006, 63:679-685.
135. Olfson M., Marcus S.C. National trends in outpatient psychotherapy. The American Journal of Psychiatry 2010, 167:1456-1463.
136. Open Letter to the DSM-5 (n.d.). Retrieved February 4, 2013, from. http://www.ipetitions.com/petition/dsm5/.
137. Otsuka-America Pharmaceuticals Abilify advertisement Retrieved February 18, 2012, from. http://books.google.com/books?id=ecoDAAAAMBAJ&pg=PA133&lpg=PA133&dq=%22When+activity+of+key+brain+chemicals+is+too+high,+Abilify+lowers+it.+When+activity+of+key+brain+chemicals+is+too+low,+Abilify+raises+it%22&source=bl&ots=djCtDQ9wPk&sig=mTSm8gM1vgQSfvTj4ZeKbkZJIcs&hl=en&sa=X&ei=6C5AT6mzJ4iU2wXezKGaCA&ved=0CDMQ6AEwAw#v=onepage&q=%22When%20activity%20of%20key%20brain%20chemicals%20is%20too%20high%2C%20Abilify%20lowers%20it.%20When%20activity%20of%20key%20brain%20chemicals%20is%20too%20low%2C%20Abilify%20raises%20it%22&f=false.
138. Otto M.W., Pollack M.H., Sabatino S.A. Maintenance of remission following cognitive-behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment. Behavior Therapy 1996, 27:473-482.
139. Textbook of biological psychiatry 2004, Wiley-Liss, Hoboken, NJ. J. Panksepp (Ed.).
140. Papakostas G.I., Shelton R.C., Kinrys G., Henry M.E., Bakow B.R., Pi B., et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: A pilot and replication study. Molecular Psychiatry 2013, 18:332-339.
141. Pediatric OCD Treatment Study (POTS) Team Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of the American Medical Association 2004, 292:1969-1976.
142. Peele S. Reductionism in the psychology of the eighties: Can biochemistry eliminate addiction, mental illness, and pain?. American Psychologist 1981, 36:807-818.
143. Peele S. Diseasing of America: How we allowed recovery zealots and the treatment industry to convince us we are out of control 1989, Jossey-Bass, San Francisco.
144. Perälä J., Suvisaari J., Saarni S.I., Kuoppasalmi K., Isometsä E., Pirkola S., et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry 2007, 64:19-28.
145. Pescosolido B.A., Martin J.K., Long J.S., Medina T.R., Phelan J.C., Link B.G. A disease like any other? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. The American Journal of Psychiatry 2010, 167:1321-1330.
146. Phelan J.C. Geneticization of deviant behavior and consequences for stigma: The case of mental illness. Journal of Health and Social Behavior 2005, 46:307-322.
147. Pies R. Psychiatry's new brain-mind and the legend of the "chemical imbalance" [Electronic version]. Psychiatric News 2011, July 11, (Retrieved February 18, 2012, fromhttp://www.psychiatrictimes.com/blog/couchincrisis/content/article/10168/1902106).
148. Pigott H.E. STAR*D: A tale and trail of bias. Ethical Human Psychology and Psychiatry 2011, 13:6-28.
149. Pilecki B.C., Clegg J.W., McKay D. The influence of corporate and political interests on models of illness in the evolution of the DSM. European Psychiatry 2011, 26:194-200.
150. Pratt L.A., Brody D.J., Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief, No 76 2011, National Center for Health Statistics, Hyattsville, MD.
151. Rapee R.M., Gaston J.E., Abbott M.J. Testing the efficacy of theoretically derived improvements in the treatment of social phobia. Journal of Consulting and Clinical Psychology 2009, 77:317-327.
152. Read J., Haslam N., Sayce L., Davies E. Prejudice and schizophrenia: A review of the "mental illness is an illness like any other" approach. Acta Psychiatrica Scandinavica 2006, 114:1-16.
153. Dx Revision Watch Three professional organization responses to third and final DSM-5 stakeholder review Retrieved June 25, 2012, from. http://dxrevisionwatch.wordpress.com/2012/06/21/three-professional-organization-responses-to-third-and-final-dsm-5-stakeholder-review/.
154. Rosen G., Davison G. Psychology should list empirically supported principles of change (ESPs) and not credential trademarked therapies or other treatment packages. Behavior Modification 2003, 27:300-312.
155. Rush A.J., Madhukar H., Trivedi S.R., Wisniewski S.R., Nierenberg A.A., Stewart J.W., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. The American Journal of Psychiatry 2006, 163:1905-1917.
156. Sabshin M. Report of the medical director. The American Journal of Psychiatry 1981, 138:1418-1421.
157. Sabshin M. Report of the medical director. The American Journal of Psychiatry 1988, 145:1338-1342.
158. Schatzberg A.F. Presidential address. The American Journal of Psychiatry 2010, 167:1162-1165.
159. Schilkraudt J.J. The catecholamine hypothesis of affective disorders: A review of supporting evidence. The American Journal of Psychiatry 1965, 122:509-522.
160. Schneck C.D., Miklowitz D.J., Miyahara S., Araga M., Wisniewski S., Gyulai L., et al. The prospective course of rapid-cycling bipolar disorder: Findings from the STEP-BD. The American Journal of Psychiatry 2008, 165:370-377.
161. Schomerus G., Schwahn C., Holzinger A., Corrigan P.W., Grabe H.J., Carta M.G., et al. Evolution of public attitudes about mental illness: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica 2012, 125:440-452.
162. Shapiro F. Eye movement desensitization and reprocessing (EMDR): Basic principles, protocols, and procedures 2001, Guildford Press, New York. 2nd ed.
163. Sikich L., Frazier J.A., McClellan J., Findling R.L., Vitiello B., Ritz L., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. The American Journal of Psychiatry 2008, 165:1420-1431.
164. Spiegel A. When it comes to depression, serotonin isn't the whole story Retrieved February 18, 2012, from. http://www.npr.org/blogs/health/2012/01/23/145525853/when-it-comes-to-depression-serotonin-isnt-the-whole-story.
165. Stahl L. Treating depression: Is there a placebo effect? 60 Minutes Retrieved March 6, 2012, from. http://www.cbsnews.com/8301-18560_162-57380893/treating-depression-is-there-a-placebo-effect/.
166. Stewart R.E., Chambless D.L. Cognitive-behavioral therapy for adult anxiety disorders in clinical practice: A meta-analysis of effectiveness studies. Journal of Consulting and Clinical Psychology 2009, 77:595-606.
167. Stirman S.W., DeRubeis R.J., Crits-Cristoph, Brody Are samples in randomized controlled trials of psychotherapy representative of community outpatients? A new methodology and initial findings. Journal of Consulting and Clinical Psychology 2003, 71:963-972.
168. Stirman S.W., DeRubeis R.J., Crits-Cristoph, Rothman A. Can the randomized controlled trial literature generalize to nonrandomized patients?. Journal of Consulting and Clinical Psychology 2005, 73:127-135.
169. Szasz T. The myth of mental illness: Foundations of a theory of personal conduct 1961, Harper & Row, New York.
170. Szasz T. Pharmacracy: Medicine and politics in America 2001, Praeger, Westport, CT.
171. Taylor S., McKay D., Abramowitz J.S. More on the brain disease model of mental disorders. The Behavior Therapist 2010, 33:16-17.
172. The WHO World Mental Health Survey Consortium Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. Journal of the American Medical Association 2004, 291:2581-2590.
173. U.S.Department of Health and Human Services Mental health: A report of the Surgeon General 1999, U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville, MD.
174. van Gerven J., Cohen A. Vanishing clinical psychopharmacology. British Journal of Clinical Pharmacology 2011, 72:1-5.
175. van Rossum J.M. The significance of dopaminereceptor blockade for the action of neuroleptic drugs 1967, 321-329. Neuropsychopharmacology excerpta Medica Foundation, Amsterdam.
176. Volkow, N. (n.d.). Director's page. Retrieved February 18, 2012, from. http://www.drugabuse.gov/about-nida/directors-page.
177. Wampold B.E. The great psychotherapy debate: Models, methods, and findings 2001, Routledge, New York.
178. Wampold B.E., Hollon S.D., Hill C.E. Unresolved questions and future directions in psychotherapy research. History of psychotherapy: Continuity and change 2011, American Psychological Association, Washington, DC. 2nd ed. J.C. Norcross, G.R. VandenBos, D.K. Freedheim (Eds.).
179. Watson A., Otey E., Westbrook A., Gardner A., Lamb T., Corrigan P., et al. Changing middle schoolers' attitudes about mental illness through education. Schizophrenia Bulletin 2004, 30:563-572.
180. WebMD Depression screening - Topic overview Retrieved February 18, 2012, from. http://www.webmd.com/depression/tc/depression-screening-topic-overview.
181. Weissman M.M., Verdeli H., Gameroff M.J., Bledsoe S.E., Betts K., Mufson L., et al. National survey of psychotherapy training in psychiatry, psychology, and social work. Archives of General Psychiatry 2006, 63:925-934.
182. Weisz J.R., Chorpita B.F., Palinkas L.A., Schoenwald S.K., Miranda J., Bearman S.K., et al. Testing standard and modular designs for psychotherapy treating depression, anxiety, and conduct problems in youth: A randomized effectiveness trial. Archives of General Psychiatry 2012, 69:274-282.
183. Evidence-based psychotherapies for children and adolescents 2010, Guilford Press, New York. 2nd ed. J.R. Weisz, A.E. Kazdin (Eds.).
184. Westen D., Novotny C.M., Thompson-Brenner H. The empirical status of empirically supported psychotherapies: Assumptions, findings, and reporting in controlled clinical trials. Psychological Bulletin 2004, 130:631-663.
185. Whitaker R. Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill 2001, Basic Books, New York.
186. Whitaker R. Anatomy of an epidemic: Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America 2010, Crown, New York.
187. Whitaker R. SAMHSA, alternatives, and the story of an opportunity lost Retrieved June 29, 2012, from. http://www.madinamerica.com/2010/10/%ef%bb%bfsamhsa-alternatives-and-the-story-of-an-opportunity-lost/.
188. Whitaker R. SAMHSA, alternatives, and a psychiatrist's despair over the state of American science Retrieved June 29, 2012, from. http://www.madinamerica.com/2010/10/%ef%bb%bfsamhsa-alternatives-and-a-psychiatrists-despair-over-the-state-of-american-science/.
189. Whitaker R. Speaking at MGH grand rounds, and more Retrieved June 29, 2012, from. http://www.madinamerica.com/2011/01/%ef%bb%bfspeaking-at-mgh-grand-rounds-and-more/.
190. Wolfe T. Group vowing to find cure for brain diseases gains momentum Retrieved August 1, 2012, from. http://psychnews.psychiatryonline.org/newsArticle.aspx?articleid=1157590.
191. World Health Organization Global status report on non-communicable diseases 2010 2011, WHO, Geneva.